Latest Scheme Of Arrangement News

Apiam Animal Health Limited has entered a binding agreement with Adamantem Capital Fund II for a $228.4 million acquisition via a scheme of arrangement, offering shareholders a significant premium and flexible cash or scrip consideration options.

Lynch Group Holdings Limited proposes a scheme of arrangement for acquisition by Hasfarm Bidco at a 23% premium, with unanimous board support and an independent expert endorsement. Shareholders will vote in November on a deal that would delist Lynch from the ASX.

Lynch Group Holdings Limited is moving closer to a $269 million acquisition by Hasfarm Bidco, with a shareholder meeting scheduled for 21 November 2025 to vote on the proposed scheme of arrangement. The transaction offers Lynch shareholders a 23% premium and is backed by an independent expert report and unanimous board recommendation.

Duxton Farms has secured Federal Court approval to merge four private agricultural companies, setting the stage for a significant expansion in walnuts, dried fruits, orchards, and bees. The merger is expected to complete by the end of October, accompanied by new financing arrangements.

Mayne Pharma has announced the rescheduling of its Supreme Court hearing to November 3, 2025, to approve the acquisition scheme by Cosette Australia BidCo, pending Foreign Investment Review Board approval.

Vonex Limited has finalized its Scheme of Arrangement, transferring all shares to Maxo Telecommunications and initiating a board overhaul ahead of its imminent ASX delisting.

United States Antimony Corporation has proposed acquiring Larvotto Resources in a deal that could create one of the largest antimony producers outside China, offering Larvotto shareholders a significant premium.

United States Antimony Corporation has made a non-binding indicative offer to acquire Larvotto Resources at a significant premium, proposing a strategic merger focused on antimony supply chain security and growth.

The ASX has granted key waivers allowing Southern Cross Media to proceed with its acquisition of Seven West Media without shareholder approval, smoothing the way for a major media consolidation.

Mayne Pharma’s planned acquisition by Cosette Pharmaceuticals faces a delay as the Foreign Investment Review Board postpones its decision, potentially pushing back key court proceedings.

Mayne Pharma has won a key legal battle against Cosette Pharmaceuticals, clearing the way for its acquisition scheme to proceed pending final approvals. Shareholders can expect the deal to move forward with payments scheduled soon.

NSX Limited’s shares have been suspended from trading following Federal Court approval of its acquisition by an Ontario-based entity linked to CNSX Markets Inc. This marks a significant shift in ownership for the Australian stock exchange operator.